Review of trials currently testing treatment and prevention of COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.04.27.20080226: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Although the number of identified trials was high, there were several methodological caveats. Firstly, study design data and details on the interventions being assessed were often lacking. This hampers the available information …
SciScore for 10.1101/2020.04.27.20080226: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Although the number of identified trials was high, there were several methodological caveats. Firstly, study design data and details on the interventions being assessed were often lacking. This hampers the available information to researchers and relevant stakeholders, and potentially influences the discovery of successful treatments. Secondly, most trials, and especially those registered at the beginning of the pandemic, disclosed low participant numbers, which may impact the robustness of their future results. However, these numbers should be cautiously interpreted, as they represent the anticipated, and not the actual number of inclusions. Thirdly, reported primary endpoints were highly heterogeneous among studies. In our opinion, the applicationof clinical primary endpoints should be encouraged in an infection where the association between the clinical status and viral clearance, radiological or immunological evolution is obscure. The identification of the best therapeutic approach is challenging, especially in the context of a pandemic with thousands of casualties. Our study underlines the need to meticulously register as many study details as possible on international registries during outbreaks, in order to guide the development and enhance the consistency of future trials. The development of clinical trials during an outbreak is an adaptive process and new evidence emerges at an impressive rate. A review of the early registered clinical trials is an important asset fo...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04308668 Completed Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coro… NCT04303507 Recruiting Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Di… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-